{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T13:23:47Z","timestamp":1780493027170,"version":"3.54.1"},"reference-count":42,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of Geriatric Pharmacotherapy"],"published-print":{"date-parts":[[2006,6]]},"DOI":"10.1016\/j.amjopharm.2006.06.001","type":"journal-article","created":{"date-parts":[[2006,7,21]],"date-time":"2006-07-21T14:53:07Z","timestamp":1153493587000},"page":"112-122","source":"Crossref","is-referenced-by-count":19,"title":["Tolerability of atorvastatin in a population aged \u226565 years: A retrospective pooled analysis of results from fifty randomized clinical trials"],"prefix":"10.1016","volume":"4","author":[{"given":"Judith H.","family":"Hey-Hadavi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Kuntze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Silverman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Pittman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"LePetri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjopharm.2006.06.001_bib1","series-title":"National Health and Nutrition Examination Survey","author":"Centers for Disease Control and Prevention (CDC)\/ National Center for Health Statistics","year":"2006"},{"key":"10.1016\/j.amjopharm.2006.06.001_bib2","series-title":"Heart Disease and Stroke Statistics-2005 Update","author":"American Heart Association (AHA)","year":"2005"},{"key":"10.1016\/j.amjopharm.2006.06.001_bib3","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1161\/01.CIR.0000035036.22612.2B","article-title":"World Heart Day 2002: The international burden of cardiovascular disease: Responding to the emerging global epidemic","volume":"106","author":"Bonow","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.amjopharm.2006.06.001_bib4","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(86)90597-0","article-title":"Serum cholesterol, blood pressure, and mortality: Implications from a cohort of 361,662 men","volume":"2","author":"Martin","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.amjopharm.2006.06.001_bib5","first-page":"750","article-title":"State-specific cholesterol screening trends-United States, 1991\u20131999","volume":"49","author":"Centers for Disease Control and Prevention (CDC)","year":"2000","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.amjopharm.2006.06.001_bib6","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/oxfordjournals.aje.a008724","article-title":"Total and high density lipoprotein cholesterol as risk factors for coronary heart disease in elderly men during 5 years of follow-up. The Zutphen Elderly Study","volume":"143","author":"Weijenberg","year":"1996","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.amjopharm.2006.06.001_bib7","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1046\/j.1365-2796.2003.01200.x","article-title":"Total cholesterol and mortality in the elderly","volume":"254","author":"Casiglia","year":"2003","journal-title":"J Intern Med"},{"key":"10.1016\/j.amjopharm.2006.06.001_bib8","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.amjopharm.2006.06.001_bib9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/ BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.amjopharm.2006.06.001_bib10","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","article-title":"PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial","volume":"360","author":"Shepherd","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.amjopharm.2006.06.001_bib11","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ahj.2004.06.003","article-title":"Impact of age on management and outcome of acute coronary syndrome: Observations from the Global Registry of Acute Coronary Events (GRACE)","volume":"149","author":"Avezum","year":"2005","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjopharm.2006.06.001_bib12","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1016\/S0735-1097(02)02477-4","article-title":"Statin therapy is associated with reduced mortality across all age groups of individuals with significant coronary disease, including very elderly patients","volume":"40","author":"Allen Maycock","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjopharm.2006.06.001_bib13","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.ahj.2003.11.028","article-title":"Effect of age on the use of evidence-based therapies for acute myocardial infarction","volume":"148","author":"Tran","year":"2004","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjopharm.2006.06.001_bib14","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","volume":"361","author":"Sever","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.amjopharm.2006.06.001_bib15","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.amjopharm.2006.06.001_bib16","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjopharm.2006.06.001_bib17","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjopharm.2006.06.001_bib18","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/S0002-9149(03)00820-8","article-title":"Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients","volume":"92","author":"Newman","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjopharm.2006.06.001_bib19","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0021-9150(99)00294-4","article-title":"Safety profile of atorvastatin-treated patients with low LDL-cholesterol levels","volume":"149","author":"Bakker-Arkema","year":"2000","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.amjopharm.2006.06.001_bib20","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.amjcard.2004.09.015","article-title":"Long-term safety and efficacy of high-dose atorvastatin treatment in patients with familial hypercholesterolemia","volume":"95","author":"van Wissen","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjopharm.2006.06.001_bib21","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1001\/jama.291.9.1071","article-title":"Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: A randomized controlled trial","volume":"291","author":"Nissen","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.amjopharm.2006.06.001_bib22","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1161\/01.CIR.0000090686.57897.F5","article-title":"Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease","volume":"108","author":"Mohler","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.amjopharm.2006.06.001_bib23","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1056\/NEJM199907083410202","article-title":"Aggressive lipid-lowering therapy compared with angio plasty in stable coronary artery disease","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjopharm.2006.06.001_bib24","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1001\/jama.285.13.1711","article-title":"Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial","volume":"285","author":"Schwartz","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.amjopharm.2006.06.001_bib25","first-page":"1772","article-title":"Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: The alliance study","volume":"44","author":"Koren","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjopharm.2006.06.001_bib26","series-title":"Guideline for Good Clinical Practice","author":"European Agency for the Evaluation of Medicinal Products, International Conference on HarmonisationWorld Health Organization","year":"2002"},{"key":"10.1016\/j.amjopharm.2006.06.001_bib27","series-title":"COSTART:: Coding Symbols for Thesaurus of Adverse Reaction Terms","author":"US Food and Drug Administration (FDA), Dept of Health and Human Services","year":"1993"},{"key":"10.1016\/j.amjopharm.2006.06.001_bib28","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/archinte.163.5.553","article-title":"Risk for myopathy with statin therapy in high-risk patients","volume":"163","author":"Ballantyne","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.amjopharm.2006.06.001_bib29","doi-asserted-by":"crossref","first-page":"28J","DOI":"10.1016\/0002-9149(88)90004-5","article-title":"Efficacy and long-term adverse effect pattern of lovastatin","volume":"62","author":"Tobert","year":"1988","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjopharm.2006.06.001_bib30","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0735-1097(02)02030-2","article-title":"ACC\/AHA\/NHLBI clinical advisory on the use and safety of statins","volume":"40","author":"Pasternak","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjopharm.2006.06.001_bib31","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1161\/01.CIR.0000034508.55617.65","article-title":"ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: A randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness","volume":"106","author":"Taylor","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.amjopharm.2006.06.001_bib32","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1002\/j.1552-4604.1997.tb04288.x","article-title":"Atorvastatin does not alter the anticoagulant activity of warfarin","volume":"37","author":"Stern","year":"1997","journal-title":"J Clin Pharmacol"},{"issue":"Suppl A","key":"10.1016\/j.amjopharm.2006.06.001_bib33","doi-asserted-by":"crossref","first-page":"336A","DOI":"10.1016\/S0735-1097(03)82024-7","article-title":"An examination of atorvastatin safety when used in combination with verapamil. Evidence from 44 completed clinical trials","volume":"41","author":"Sasiela","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjopharm.2006.06.001_bib34","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/S1567-5688(03)90365-5","article-title":"An examination of atorvastatin safety when used in combination with amiodarone: Evidence from 44 completed clinical trials","volume":"4","author":"Sasiela","year":"2003","journal-title":"Atherosclerosis Suppl"},{"key":"10.1016\/j.amjopharm.2006.06.001_bib35","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1001\/archinte.164.18.2051","article-title":"Absence of interaction between atorvastatin or other statins and clopidogrel: Results from the interaction study","volume":"164","author":"Serebruany","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.amjopharm.2006.06.001_bib36","first-page":"253","article-title":"Lipidaltering efficacy and safety of simvastatin 80 mg\/day: Worldwide long-term experience in patients with hypercholesterolemia","volume":"10","author":"Davidson","year":"2000","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.amjopharm.2006.06.001_bib37","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jama.292.11.1307","article-title":"Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syn dromes: Phase Z of the A to Z trial","volume":"292","author":"de Lemos","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.amjopharm.2006.06.001_bib38","series-title":"Zocor (simvastatin) [prescribing information]","year":"2005"},{"key":"10.1016\/j.amjopharm.2006.06.001_bib39","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.jacc.2005.04.064","article-title":"Can lowdensity lipoprotein be too low? The safety and efficacy of achieving very low-density lipoprotein with intensive statin therapy: PROVE IT-TIMI 22 substudy","volume":"46","author":"Wiviott","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjopharm.2006.06.001_bib40","series-title":"Lipitor (atorvastatin calcium) [prescribing information]","year":"2005"},{"key":"10.1016\/j.amjopharm.2006.06.001_bib41","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1136\/bmj.300.6720.297","article-title":"Microalbuminuria as predictor of increased mortality in elderly people","volume":"300","author":"Damsgaard","year":"1990","journal-title":"BMJ"},{"issue":"Suppl 3","key":"10.1016\/j.amjopharm.2006.06.001_bib42","first-page":"S1","article-title":"K\/DOQI Clinical practice guidelines for managing dyslipidemias in chronic kidney disease","volume":"41","author":"National Kidney Foundation (NKF)","year":"2003","journal-title":"Am J Kidney Dis"}],"container-title":["The American Journal of Geriatric Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1543594606000237?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1543594606000237?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,14]],"date-time":"2019-01-14T18:53:23Z","timestamp":1547492003000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1543594606000237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["S1543594606000237"],"URL":"https:\/\/doi.org\/10.1016\/j.amjopharm.2006.06.001","relation":{},"ISSN":["1543-5946"],"issn-type":[{"value":"1543-5946","type":"print"}],"subject":[],"published":{"date-parts":[[2006,6]]}}}